About Relmada Therapeutics, Inc.
https://www.relmada.comRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
CEO
Sergio Traversa
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-09-30 | Reverse | 1:4 |
| 2015-08-12 | Reverse | 1:5 |
ETFs Holding This Stock
PSIL
Weight:7.25%
Shares:335.94K
VXF
Weight:0.00%
Shares:302.33K
DX2D.DE
Weight:0.23%
Shares:224.74K
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
IKARIAN CAPITAL, LLC
Shares:1.84M
Value:$7.08M
VHCP MANAGEMENT III, LLC
Shares:767.94K
Value:$2.95M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:740.01K
Value:$2.84M
Summary
Showing Top 3 of 60
About Relmada Therapeutics, Inc.
https://www.relmada.comRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.33M ▲ | $-10.09M ▼ | 0% | $-0.3 | $-10.09M ▲ |
| Q2-2025 | $0 | $10.22M ▼ | $-9.87M ▲ | 0% | $-0.3 ▲ | $-10.22M ▲ |
| Q1-2025 | $0 | $18.22M ▼ | $-17.56M ▲ | 0% | $-0.58 ▲ | $-18.22M ▼ |
| Q4-2024 | $0 | $19.08M ▼ | $-18.66M ▲ | 0% | $-0.62 ▲ | $0 ▲ |
| Q3-2024 | $0 | $23.01M | $-21.73M | 0% | $-0.72 | $-1K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $13.89M ▼ | $14.88M ▼ | $5.41M ▲ | $9.47M ▼ |
| Q2-2025 | $20.62M ▼ | $21.12M ▼ | $5.17M ▼ | $15.95M ▼ |
| Q1-2025 | $27.06M ▼ | $27.68M ▼ | $5.24M ▼ | $22.44M ▼ |
| Q4-2024 | $44.91M ▼ | $45.82M ▼ | $10.3M ▲ | $35.52M ▼ |
| Q3-2024 | $54.12M | $55.72M | $8.1M | $47.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.09M ▼ | $-6.72M ▼ | $6.75M ▲ | $0 ▲ | $31.13K ▼ | $-6.72M ▼ |
| Q2-2025 | $-9.87M ▲ | $-6.4M ▲ | $6.68M ▼ | $-73.02K ▼ | $203.65K ▲ | $-6.4M ▲ |
| Q1-2025 | $-17.56M ▲ | $-18.07M ▼ | $15.36M ▲ | $0 ▲ | $-2.71M ▼ | $-18.07M ▼ |
| Q4-2024 | $-18.66M ▲ | $-8.8M ▲ | $11.35M ▼ | $-172.49K ▼ | $2.37M ▲ | $-8.8M ▲ |
| Q3-2024 | $-21.73M | $-16.66M | $16.14M | $-89.6K | $-602.47K | $-16.66M |
CEO
Sergio Traversa
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-09-30 | Reverse | 1:4 |
| 2015-08-12 | Reverse | 1:5 |
ETFs Holding This Stock
PSIL
Weight:7.25%
Shares:335.94K
VXF
Weight:0.00%
Shares:302.33K
DX2D.DE
Weight:0.23%
Shares:224.74K
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
IKARIAN CAPITAL, LLC
Shares:1.84M
Value:$7.08M
VHCP MANAGEMENT III, LLC
Shares:767.94K
Value:$2.95M
DRIEHAUS CAPITAL MANAGEMENT LLC
Shares:740.01K
Value:$2.84M
Summary
Showing Top 3 of 60